Welcome to our dedicated page for Quipt Home Medical SEC filings (Ticker: QIPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quipt Home Medical Corp. (QIPT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, with AI-powered tools to help interpret complex documents. Quipt is a British Columbia corporation whose common shares trade on The Nasdaq Capital Market and the Toronto Stock Exchange, and it files reports with the U.S. Securities and Exchange Commission in connection with its status as a reporting issuer.
Among the key filings for Quipt are its Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, management’s discussion and analysis, and details on its home medical equipment and in-home respiratory care business in the United States healthcare market. These filings expand on topics referenced in press releases, such as recurring revenue from equipment rentals and respiratory resupplies, non-GAAP measures like Adjusted EBITDA, and risk factors related to reimbursement, regulation, and acquisitions.
Quipt also files Form 8-K current reports to disclose material events. Recent examples include an August 11, 2025 Form 8-K furnishing a press release on fiscal third quarter 2025 results, an August 12, 2025 Form 8-K describing the Equity Purchase Agreement for a 60% interest in Hart Medical Equipment, and a July 7, 2025 Form 8-K discussing the acquisition of a Ballad Health-owned durable medical equipment provider. On December 15, 2025, Quipt filed a Form 8-K detailing its entry into an Arrangement Agreement under which entities affiliated with Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for US$3.65 per share in cash.
These filings explain that, if the arrangement is consummated, Quipt’s shares will be delisted from The Nasdaq Capital Market and the Toronto Stock Exchange, de-registered under the Securities Exchange Act of 1934, and Quipt will cease to be a reporting issuer under Canadian securities laws. Until that transaction closes, investors can use this page to review Quipt’s ongoing SEC disclosures, including 8-Ks related to financial results, acquisitions, joint ventures, and the planned going-private transaction.
Stock Titan’s interface surfaces real-time updates from EDGAR and applies AI-generated summaries to help users quickly understand the contents of lengthy filings, including the implications of transaction agreements, non-GAAP reconciliations, and other technical disclosures related to Quipt’s home medical equipment and respiratory care operations.
Quipt Home Medical Corp. reported results for the quarter and nine months ended June 30, 2025. Revenue for the quarter was $58.3 million, down 4.1% from $60.8 million a year earlier, and nine-month revenue was $177.0 million versus $184.6 million. The company recorded a quarterly net loss of $3.0 million (basic loss per share $0.07) and a nine-month net loss of $7.2 million (basic loss per share $0.17), both larger than the prior-year periods. Adjusted EBITDA remained positive at $13.7 million for the quarter and $41.0 million for nine months.
Quipt ended the period with $11.25 million of cash and total assets of $236.1 million against total liabilities of $133.6 million. The Company was in compliance with its senior credit facility covenants and had $66.0 million principal outstanding under that facility. Management disclosed a DOJ civil investigative demand related to CPAP claims and noted the SEC concluded its inquiry in November 2024. After period end, Quipt acquired Mediserve for approximately $2.6 million. The Company performed an interim goodwill impairment test following market declines and identified no impairment.